These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 34255320)
1. Fibroblast Growth Factor Receptor-4 Expression in Pituitary Adenomas is Associated with Aggressive Tumor Features. Durcan E; Keskin FE; Ozkaya HM; Sirolu S; Sahin S; Korkmaz OP; Gazioglu N; Tanriover N; Comunoglu N; Oz B; Kizilkilic O; Kadioglu P Exp Clin Endocrinol Diabetes; 2022 Feb; 130(2):125-133. PubMed ID: 34255320 [TBL] [Abstract][Full Text] [Related]
2. Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. Ramírez C; Cheng S; Vargas G; Asa SL; Ezzat S; González B; Cabrera L; Guinto G; Mercado M J Clin Endocrinol Metab; 2012 May; 97(5):1745-51. PubMed ID: 22419713 [TBL] [Abstract][Full Text] [Related]
3. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas. Grimm F; Maurus R; Beschorner R; Naros G; Stanojevic M; Gugel I; Giese S; Bier G; Bender B; Honegger J Acta Neurochir (Wien); 2019 Jun; 161(6):1149-1156. PubMed ID: 31037500 [TBL] [Abstract][Full Text] [Related]
4. Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. Qian ZR; Sano T; Asa SL; Yamada S; Horiguchi H; Tashiro T; Li CC; Hirokawa M; Kovacs K; Ezzat S J Clin Endocrinol Metab; 2004 Apr; 89(4):1904-11. PubMed ID: 15070963 [TBL] [Abstract][Full Text] [Related]
5. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744 [TBL] [Abstract][Full Text] [Related]
6. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables. Matsuyama J Neurol Med Chir (Tokyo); 2012; 52(8):563-9. PubMed ID: 22976139 [TBL] [Abstract][Full Text] [Related]
7. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry]. Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431 [TBL] [Abstract][Full Text] [Related]
8. Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. Mastronardi L; Guiducci A; Puzzilli F BMC Cancer; 2001; 1():12. PubMed ID: 11570981 [TBL] [Abstract][Full Text] [Related]
9. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas. Hasanov R; Aydoğan Bİ; Kiremitçi S; Erden E; Güllü S Endocr Pathol; 2019 Mar; 30(1):49-55. PubMed ID: 30610566 [TBL] [Abstract][Full Text] [Related]
10. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas. Wolfsberger S; Kitz K; Wunderer J; Czech T; Boecher-Schwarz HG; Hainfellner JA; Knosp E Acta Neurochir (Wien); 2004 Dec; 146(12):1323-7; discussion 1327-8. PubMed ID: 15480830 [TBL] [Abstract][Full Text] [Related]
11. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. Meij BP; Lopes MB; Ellegala DB; Alden TD; Laws ER J Neurosurg; 2002 Feb; 96(2):195-208. PubMed ID: 11838791 [TBL] [Abstract][Full Text] [Related]
12. Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas. Lee JC; Pekmezci M; Lavezo JL; Vogel H; Katznelson L; Fraenkel M; Harsh G; Dulai M; Perry A; Tihan T Endocr Pathol; 2017 Dec; 28(4):287-292. PubMed ID: 28994039 [TBL] [Abstract][Full Text] [Related]